Professional continuous glucose monitoring in patients with diabetes mellitus: A systematic review and meta-analysis.


Journal

Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645

Informations de publication

Date de publication:
05 2023
Historique:
revised: 11 01 2023
received: 04 12 2022
accepted: 17 01 2023
medline: 4 4 2023
pubmed: 21 1 2023
entrez: 20 1 2023
Statut: ppublish

Résumé

To evaluate the effect on glucose control of professional continuous glucose monitoring (p-CGM)-based care as compared with standard care in the management of patients with type 1 and type 2 diabetes. The PubMed database was searched comprehensively to identify prospective or retrospective studies evaluating p-CGM as a diagnostic tool for subsequent implementation of lifestyle and/or medication changes and reporting glycated haemoglobin (HbA1c) as an outcome measure. We found 872 articles, 22 of which were included in the meta-analysis. Overall, the use of p-CGM was associated with greater HbA1c reduction from baseline (-0.28%, 95% confidence interval [CI] -0.36% to -0.21%, I In patients with type 1 and type 2 diabetes, p-CGM-driven care is superior to usual care in improving glucose control without increasing hypoglycaemia.

Identifiants

pubmed: 36661362
doi: 10.1111/dom.14981
doi:

Substances chimiques

Blood Glucose 0
Glycated Hemoglobin 0

Types de publication

Meta-Analysis Systematic Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1301-1310

Informations de copyright

© 2023 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Références

Di Molfetta S, Rossi A, Assaloni R, et al. A guide for the use of LibreView digital diabetes platform in clinical practice: expert paper of the Italian working group on diabetes and technology. Diabetes Res Clin Pract. 2022;187:109867. doi:10.1016/j.diabres.2022.109867
Castellana M, Parisi C, Di Molfetta S, et al. Efficacy and safety of flash glucose monitoring in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis. BMJ Open Diabetes Res Care. 2020;8(1):e001092. doi:10.1136/bmjdrc-2019-001092
Gavin JR, Bailey CJ. Real-world studies support use of continuous glucose monitoring in type 1 and type 2 diabetes independently of treatment regimen. Diabetes Technol Ther. 2021;23(S3):S19-S27. doi:10.1089/dia.2021.0211
DiMeglio LA, Acerini CL, Codner E, et al. ISPAD clinical practice consensus guidelines 2018: glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatr Diabetes. 2018;19(Suppl 27):105-114. doi:10.1111/pedi.12737
Holt RIG, DeVries JH, Hess-Fischl A, et al. The Management of Type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021;44(11):2589-2625. doi:10.2337/dci21-0043
Blevins TC. Professional continuous glucose monitoring in clinical practice 2010. J Diabetes Sci Technol. 2010;4(2):440-456. doi:10.1177/193229681000400226
Miller EM. Using continuous glucose monitoring in clinical practice. Clin Diabetes. 2020;38(5):429-438. doi:10.2337/cd20-0043
Adkison JD, Chung PE. Implementing continuous glucose monitoring in clinical practice. Fam Pract Manag. 2021;28(2):7-14.
Meng R, Gu T, Yang F, Liu J, Sun Q, Zhu D. Performance evaluation of the Glunovo® continuous blood glucose monitoring system in Chinese participants with diabetes: a multicenter, self-controlled trial. Diabetes Ther. 2021;12(12):3153-3165. doi:10.1007/s13300-021-01171-2
Longo R, Sperling S. Personal versus professional continuous glucose monitoring: when to use which on whom. Diabetes Spectr. 2019;32(3):183-193. doi:10.2337/ds18-0093
Rivera-Ávila DA, Esquivel-Lu AI, Salazar-Lozano CR, Jones K, Doubova SV. The effects of professional continuous glucose monitoring as an adjuvant educational tool for improving glycemic control in patients with type 2 diabetes. BMC Endocr Disord. 2021;21(1):79. doi:10.1186/s12902-021-00742-5
Associazione Medici Diabetologi SIdD, Società Italiana di Endocrinologia e Diabetologia Pediatrica. Documento del Gruppo di Studio Intersocietario AMD - SID - SIEDP “Tecnologia e diabete”. 2019.
Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: the use of advanced Technology in the Management of persons with diabetes mellitus. Endocr Pract. 2021;27(6):505-537. doi:10.1016/j.eprac.2021.04.008
Golicki DT, Golicka D, Groele L, Pankowska E. Continuous glucose monitoring system in children with type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetologia. 2008;51(2):233-240. doi:10.1007/s00125-007-0884-9
Ida S, Kaneko R, Murata K. Utility of real-time and retrospective continuous glucose monitoring in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. J Diabetes Res. 2019;2019:4684815-4684810. doi:10.1155/2019/4684815
Ribeiro RT, Andrade R. Nascimento do Ó D, lopes AF, Raposo JF. Impact of blinded retrospective continuous glucose monitoring on clinical decision making and glycemic control in persons with type 2 diabetes on insulin therapy. Nutr Metab Cardiovasc Dis. 2021;31(4):1267-1275. doi:10.1016/j.numecd.2020.12.024
Furler J, O'Neal D, Speight J, et al. Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial. Lancet Diabetes Endocrinol. 2020;8(1):17-26. doi:10.1016/S2213-8587(19)30385-7
Olsen U, Lindberg MF, Rose C, et al. Factors correlated with physical function 1 year after Total knee arthroplasty in patients with knee osteoarthritis: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(7):e2219636. doi:10.1001/jamanetworkopen.2022.19636
Khunti K, Seidu S, Kunutsor S, Davies M. Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: a meta-analysis. Diabetes Care. 2017;40(11):1588-1596. doi:10.2337/dc16-1925
Metelli S, Chaimani A. Challenges in meta-analyses with observational studies. Evid Based Ment Health. 2020;23:83-87.
Verde PE, Ohmann C. Combining randomized and non-randomized evidence in clinical research: a review of methods and applications. Res Synth Methods. 2015;6(1):45-62. doi:10.1002/jrsm.1122
Cosson E, Hamo-Tchatchouang E, Dufaitre-Patouraux L, Attali JR, Pariès J, Schaepelynck-Bélicar P. Multicentre, randomised, controlled study of the impact of continuous sub-cutaneous glucose monitoring (GlucoDay) on glycaemic control in type 1 and type 2 diabetes patients. Diabetes Metab. 2009;35(4):312-318. doi:10.1016/j.diabet.2009.02.006
Anjana RM, Kesavadev J, Neeta D, et al. A multicenter real-life study on the effect of flash glucose monitoring on glycemic control in patients with type 1 and type 2 diabetes. Diabetes Technol Ther. 2017;19(9):533-540.
Tanenberg R, Bode B, Lane W, et al. Use of the continuous glucose monitoring system to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clin Proc. 2004;79(12):1521-1526. doi:10.4065/79.12.1521
Ajjan RA, Jackson N, Thomson SA. Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: a pilot, multicentre, randomised controlled trial. Diab Vasc Dis Res. 2019;16(4):385-395. doi:10.1177/1479164119827456
Allen NA, Fain JA, Braun B, Chipkin SR. Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: a randomized clinical trial. Diabetes Res Clin Pract. 2008;80(3):371-379. doi:10.1016/j.diabres.2008.01.006
Blackberry ID, Furler JS, Ginnivan LE, et al. An exploratory trial of basal and prandial insulin initiation and titration for type 2 diabetes in primary care with adjunct retrospective continuous glucose monitoring: INITIATION study. Diabetes Res Clin Pract. 2014;106(2):247-255. doi:10.1016/j.diabres.2014.08.011
Fantasia KL, Stockman MC, Ju Z, et al. Professional continuous glucose monitoring and endocrinology eConsult for adults with type 2 diabetes in primary care: results of a clinical pilot program. J Clin Transl Endocrinol. 2021;24:100254. doi:10.1016/j.jcte.2021.100254
Kesavadev J, Vigersky R, Shin J, et al. Assessing the therapeutic utility of professional continuous glucose monitoring in type 2 diabetes across various therapies: a retrospective evaluation. Adv Ther. 2017;34(8):1918-1927. doi:10.1007/s12325-017-0576-x
Kim SK, Kim HJ, Kim T, et al. Effectiveness of 3-day continuous glucose monitoring for improving glucose control in type 2 diabetic patients in clinical practice. Diabetes Metab J. 2014;38(6):449-455. doi:10.4093/dmj.2014.38.6.449
Sato J, Kanazawa A, Ikeda F, et al. Effect of treatment guidance using a retrospective continuous glucose monitoring system on glycaemic control in outpatients with type 2 diabetes mellitus: a randomized controlled trial. J Int Med Res. 2016;44(1):109-121. doi:10.1177/0300060515600190
Sierra JA, Shah M, Gill MS, et al. Clinical and economic benefits of professional CGM among people with type 2 diabetes in the United States: analysis of claims and lab data. J Med Econ. 2018;21(3):225-230. doi:10.1080/13696998.2017.1390474
Yeoh E, Lim BK, Fun S, et al. Efficacy of self-monitoring of blood glucose versus retrospective continuous glucose monitoring in improving glycaemic control in diabetic kidney disease patients. Nephrology (Carlton). 2018;23(3):264-268. doi:10.1111/nep.12978
Bukara-Radujković G, Zdravković D, Lakić S. Short-term use of continuous glucose monitoring system adds to glycemic control in young type 1 diabetes mellitus patients in the long run: a clinical trial. Vojnosanit Pregl. 2011;68(8):650-654. doi:10.2298/vsp1108650b
Chase HP, Kim LM, Owen SL, et al. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics. 2001;107(2):222-226. doi:10.1542/peds.107.2.222
Chico A, Vidal-Ríos P, Subirà M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care. 2003;26(4):1153-1157. doi:10.2337/diacare.26.4.1153
Deiss D, Hartmann R, Schmidt J, Kordonouri O. Results of a randomised controlled cross-over trial on the effect of continuous subcutaneous glucose monitoring (CGMS) on glycaemic control in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes. 2006;114(2):63-67. doi:10.1055/s-2006-923887
Lagarde WH, Barrows FP, Davenport ML, Kang M, Guess HA, Calikoglu AS. Continuous subcutaneous glucose monitoring in children with type 1 diabetes mellitus: a single-blind, randomized, controlled trial. Pediatr Diabetes. 2006;7(3):159-164. doi:10.1111/j.1399-543X.2006.00162.x
Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics. 2003;111(5 Pt 1):933-938. doi:10.1542/peds.111.5.933
Raviteja KV, Kumar R, Dayal D, Sachdeva N. Clinical efficacy of professional continuous glucose monitoring in improving glycemic control among children with type 1 diabetes mellitus: an open-label randomized control trial. Sci Rep. 2019;9(1):6120. doi:10.1038/s41598-019-42555-6
Yates K, Hasnat Milton A, Dear K, Ambler G. Continuous glucose monitoring-guided insulin adjustment in children and adolescents on near-physiological insulin regimens: a randomized controlled trial. Diabetes Care. 2006;29(7):1512-1517. doi:10.2337/dc05-2315
Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA. 2017;317(4):379-387. doi:10.1001/jama.2016.19976
Lind M, Odén A, Fahlén M, Eliasson B. The shape of the metabolic memory of HbA1c: re-analysing the DCCT with respect to time-dependent effects. Diabetologia. 2010;53(6):1093-1098. doi:10.1007/s00125-010-1706-z
Lind M, Odén A, Fahlén M, Eliasson B. A systematic review of HbA1c variables used in the study of diabetic complications. Diabetes Metab Syndr Clin Res Rev. 2008;2(4):282-293.
United States Deprtment of Health and Human Services FaDA, Center for Drug Evaluation and Research Guidance for Industry. Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. Accessed 30 Dec 2022, https://www.regulations.gov/document/FDA-2008-D-0118-0003
Garber AJ. Treat-to-target trials: uses, interpretation and review of concepts. Diabetes Obes Metab. 2014;16(3):193-205. doi:10.1111/dom.12129
Dicembrini I, Cosentino C, Monami M, Mannucci E, Pala L. Effects of real-time continuous glucose monitoring in type 1 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2021;58(4):401-410. doi:10.1007/s00592-020-01589-3
Maiorino MI, Signoriello S, Maio A, et al. Effects of continuous glucose monitoring on metrics of glycemic control in diabetes: a systematic review with meta-analysis of randomized controlled trials. Diabetes Care. 2020;43(5):1146-1156. doi:10.2337/dc19-1459
Ajjan RA, Abougila K, Bellary S, et al. Sensor and software use for the glycaemic management of insulin-treated type 1 and type 2 diabetes patients. Diab Vasc Dis Res. 2016;13(3):211-219. doi:10.1177/1479164115624680
Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the Management of Insulin-Treated Type 2 Diabetes: a multicenter open-label randomized controlled trial. Diabetes Ther. 2017;8(1):55-73. doi:10.1007/s13300-016-0223-6
Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593-1603. doi:10.2337/dci19-0028
Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986. doi:10.1056/NEJM199309303291401
Karter A, Ackerson L, Darbinian J, et al. Self-monitoring of blood glucose levels and glycemic control: the northern California Kaiser Permanente diabetes registry. Am J Med. 2001;11(1):1-9. doi:10.1016/s0002-9343(01)00742-2
Mannucci E, Antenore A, Giorgino F, Scavini M. Effects of structured versus unstructured self-monitoring of blood glucose on glucose control in patients with non-insulin-treated type 2 diabetes: a meta-analysis of randomized controlled trials. J Diabetes Sci Technol. 2018;12(1):183-189. doi:10.1177/1932296817719290
Di Molfetta S, Bosi E, Ceriello A, et al. Structured self-monitoring of blood glucose is associated with more appropriate therapeutic interventions than unstructured self-monitoring: a novel analysis of data from the PRISMA trial. Diabetes Res Clin Pract. 2021;181:109070. doi:10.1016/j.diabres.2021.109070
Parkin CG, Buskirk A, Hinnen DA, Axel-Schweitzer M. Results that matter: structured vs. unstructured self-monitoring of blood glucose in type 2 diabetes. Diabetes Res Clin Pract. 2012;97(1):6-15. doi:10.1016/j.diabres.2012.03.002
Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. Diabetes Technol Ther. 2019;21(2):66-72. doi:10.1089/dia.2018.0384
Edelman S, Bruttomesso D, Close KL, et al. 851-P: technology use by age and region in adults with type 1 diabetes (T1D) in the SAGE study. Diabetes. 2020;69:851-P.
Pitocco D, Laurenzi A, Tomaselli L, et al. Health care organization and use of technological devices in people with diabetes in Italy: results from a survey of the working group on diabetes and technology. Nutr Metab Cardiovasc Dis. 2022;32:2392-2398. doi:10.1016/j.numecd.2022.07.003
Isaacs D, Bellini NJ, Biba U, Cai A, Close KL. Health care disparities in use of continuous glucose monitoring. Diabetes Technol Ther. 2021;23(S3):S81-S87. doi:10.1089/dia.2021.0268

Auteurs

Sergio Di Molfetta (S)

Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.

Irene Caruso (I)

Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.

Angelo Cignarelli (A)

Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.

Annalisa Natalicchio (A)

Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.

Sebastio Perrini (S)

Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.

Luigi Laviola (L)

Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.

Francesco Giorgino (F)

Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH